Safety of β-adrenergic blocker washout period in clinical trials

Acta Ophthalmologica Scandinavica

Volumn 75, Issue 1, 1997, Pages 94-95

  Stroman, Gesa A ^a   Stewart, William C ^a,b   Stewart, Jeanette A ^a   Deitz, Tonya M ^a  

^a Clin Neurosci 67 Pres St C   (United States)

^b Pharmaceutical Research Corporation   (United States)

Author keywords

Chronic open angle glaucoma; Clinical research; Glaucomatous progression; Ocular hypertension; adrenergic blocker

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT;

ARTICLE; CLINICAL ARTICLE; DRUG SAFETY; HUMAN; INTRAOCULAR HYPERTENSION; INTRAOCULAR PRESSURE; OPEN ANGLE GLAUCOMA; OPTIC DISK; PRIORITY JOURNAL; TOPICAL DRUG ADMINISTRATION;

EID: 0030938386     PISSN: 13953907     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1600-0420.1997.tb00259.x     Document Type: Article

References (3)

1. Schlecht LP & Brubaker RF (1988): The effects of withdrawal of timolol in chronically treated glaucoma patients. Ophthalmology 95: 1212-1216.
2. Stewart WC, Ritch R, Shin DH, Lehmann RP, Shrader CE & van Buskirk EM (1995): The efficacy of apraclonidine as an adjunct to timolol therapy. Arch Ophthalmol 113: 287-292.
3. Stewart WC, Shields MB. Allen RC, Lewis R, Cohen JS, Hoskins D, Hetherington J, Bahr RL, Pollack I, Noblin J & Delehanty J (1991): A three-month comparison of 1% and 2% Carteolol and 0.5% Timolol in open-angle glaucoma. Graefe's Arch Clin Exp Ophthalmol 229: 258-261.